Natera, Inc. - Common Stock (NQ:NTRA)

416.06 +5.71 (+1.39%)

Delayed Quote Updated: 10:58 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech’s Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

Today 8:00 EDT

From Natera, Inc.

Via Business Wire

2 Growth Stocks to Stash and 1 That Underwhelm

Today 0:31 EDT

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Via StockStory

1 Unprofitable Stock to Target This Week and 2 We Question

September 30, 2026

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th...

Via StockStory

Stocks making big moves yesterday: AutoZone, Natera, Shopify, Twilio, and Lennar

September 23, 2026

Check out the companies making headlines yesterday: AutoZone (NYSE:AZO): Auto parts and accessories retailer AutoZone (NYSE:AZO) rose by 6.1% on Tuesday afte...

Via StockStory

Topics Artificial Intelligence

Why Is Natera (NTRA) Stock Soaring Today

September 22, 2026

What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA) jumped 5.2% in the afternoon session after the company announced that Japan's Pharmaceu...

Via StockStory

Signatera™ Receives Regulatory Approval in Japan as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

September 22, 2026

From Natera, Inc.

Via Business Wire

Natera CEO Steven Chapman Sells 1,698 Shares for $545,000 ↗

September 18, 2026

The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman with 98,199 directly held shares.

Via The Motley Fool

Topics Regulatory Compliance

Largest MRD Study in Lung Cancer Highlights Strong Prognostic Value for SignateraTM

September 18, 2026

From Natera, Inc.

Via Business Wire

This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters. Is It a No-Brainer Buy? ↗

September 14, 2026

The well-respected investor has Meta Platforms, Delta Air Lines, and Eli Lilly in his family office's portfolio. The stock isn't one of those.

Via The Motley Fool

3 Reasons Investors Love Natera (NTRA)

September 09, 2026

What a time it’s been for Natera. In the past six months alone, the company’s stock price has increased by a massive 59.9%, reaching $328.13 per share. This ...

Via StockStory

Billionaire Stanley Druckenmiller Has 2 Megacap Stocks Worth Watching (Hint: His Top Holding Isn't Amazon, Alphabet, or Nvidia) ↗

September 08, 2026

His largest position today is a bet on genomics.

Via The Motley Fool

Topics Artificial Intelligence Economy

Here’s How Much You Would Have Made Owning Natera Stock In The Last 10 Years ↗

September 04, 2026

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.54% on an annualized basis producing an average annual return of 40.97%. Currently, Natera has a market capitalization of...

Via Benzinga

New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma

September 01, 2026

From Natera, Inc.

Via Business Wire

3 Momentum Stocks to Own for Decades

August 31, 2026

The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, u...

Via StockStory

Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run? ↗

August 29, 2026

The billionaire has good reasons to like this genetic testing leader.

Via The Motley Fool

Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer

August 28, 2026

From Natera, Inc.

Via Business Wire

Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™

August 27, 2026

From Natera, Inc.

Via Business Wire

3 Healthcare Stocks with Promising Prospects

August 27, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

Via StockStory

Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗

August 26, 2026

Duquesne Family Office has beefed up its healthcare holdings.

Via The Motley Fool

Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either. ↗

August 24, 2026

Natera's growth, expanding role in cancer care, and growing diagnostic data platform help explain why Druckenmiller has made it a major portfolio holding, despite valuation and regulatory risks.

Via The Motley Fool

3 Large-Cap Stocks Worth Investigating

August 24, 2026

Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are...

Via StockStory

2 Biotech Stocks Shaping Up for Major Breakouts ↗

August 22, 2026

Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts.

Via MarketBeat

Topics ETFs

Billionaire Stanley Druckenmiller's Top Holding Is Up 37% This Year. Is the Market Pricing in the Full Story? ↗

August 20, 2026

The hedge fund legend has bet much of the family office on this one diagnostics company.

Via The Motley Fool

Here's How Much $1000 Invested In Natera 10 Years Ago Would Be Worth Today ↗

August 18, 2026

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.63% on an annualized basis producing an average annual return of 40.99%. Currently, Natera has a market capitalization of...

Via Benzinga

Q2 Rundown: Natera (NASDAQ:NTRA) Vs Other Biotechnology Stocks

August 17, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...

Via StockStory

Topics Artificial Intelligence

Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord Conference ↗

August 15, 2026

Natera (NASDAQ:NTRA) Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women’s health, oncology and organ health businesses, citing record...

Via MarketBeat

Natera (NTRA) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

Oncology volumes jumped 57.2% on MRD adoption gains.

Via The Motley Fool

Topics Earnings

5 Insightful Analyst Questions From Natera’s Q2 Earnings Call

August 13, 2026

Natera’s second quarter results were positively received by the market, driven by robust sales volume growth and ongoing momentum in both established and eme...

Via StockStory

Topics Earnings

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

August 12, 2026

From Natera, Inc.

Via Business Wire

What to Know About This Natera Insider Transaction as Shares Surge to Record Highs ↗

August 10, 2026

Moshkevich's non-discretionary sale was executed to cover tax withholding on vesting RSUs under a Rule 10b5-1 plan.

Via The Motley Fool

Topics Regulatory Compliance

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.